Drug intelligence / Profile preview

TR64

Development stage: Phase 1
Lead developer: Tarapeutics Science
Modality: Small Molecules
Administration: Oral

Overview

TR64 is an investigational small molecule inhibitor developed by Tarapeutics Science Inc. It targets Vascular Endothelial Growth Factor Receptors (VEGFR), Colony Stimulating Factor 1 Receptor (CSF1R), and c-KIT. It is being evaluated in a Phase I clinical study for the treatment of advanced malignant solid tumors, where it is administered orally as tablets.

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR (VEGFR family)

Beyond the preview

Go deeper on TR64.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TR64.

Explore the full profile